A Dentist’s Three Tips to Stay on Muscarinic Agonists in Sjögren's Disease Save

Resolution of dryness remains a key unmet need for patients with Sjögren disease (SjD), as highlighted by the Sjögren SIG session “How to treat SjD” on the final day of APLAR 2026 in Seoul (Sunday, November 1). 

A rheumatology talk in the session noted that recent phase III trials of ianalumab (anti-BAFF receptor), dazodalibep (CD40L antagonist) and telitacicept (TACI-IgG Fc fusion protein) improved ESSDAI scores, a measure of systemic disease activity, with only some evidence of benefit for dryness itself. Symptomatic care therefore still carries the load.

Masafumi Moriyama, DDS, PhD (Kyushu University) offered practical insight from the oral health side, using an algorithm adapted from Ramos-Casals and colleagues (Ann Rheum Dis 2020).

Before attributing dryness to SjD, he advised ruling out other contributors, since causes beyond gland damage are common: sleeping pills, anticholinergics, antidepressants, diuretics and antihistamines; dehydration or fever; mouth breathing and CPAP; candidiasis or burning mouth; smoking, alcohol, acidic drinks and sugar; and diabetes, thyroid disease or anemia.

Measuring residual saliva function can guide the therapeutic approach. Unstimulated whole saliva flow of 0.1 mL/min or more signals preserved function. If unstimulated flow is below 0.1, stimulated flow then grades dysfunction as normal or mild (above 0.7 mL/min), moderate (0.1 to 0.7) or severe (below 0.1). Non-pharmacologic stimulation comes first (e.g., sugar-free gum), then pharmacologic stimulation if response is inadequate. Severe dysfunction points to saliva substitutes (sprays, gels, artificial saliva).

Pharmacologic management with muscarinic agonists: pilocarpine versus cevimeline. When stimulation falls short, the clinical message was to consider a muscarinic agonist while gland function is preserved. Pilocarpine (5 mg tablet) and cevimeline (30 mg capsule) were each listed at three times daily after meals. Pilocarpine acts within about 20 minutes for 3 to 5 hours, while cevimeline lasts 4 to 6 hours, peaking near 2.5 hours. Adverse effects at 5% or more were sweating, urinary frequency, nausea, diarrhea and headache with pilocarpine, versus nausea and abdominal pain with cevimeline. Pilocarpine is used across Japan, Korea, China, Taiwan, the US, UK and parts of Europe, and cevimeline in Japan, Taiwan and the US. No head-to-head data were shown. If these fail or are not tolerated, the mucolytic N-acetylcysteine, choleretics and electrostimulation were noted as rescue options.

Staying on treatment. Benefit from muscarinic agonists may build over 6 to 12 months and appeared to persist over years. Yet side effects, sweating in particular, can drive patients to stop, so Dr. Moriyama suggested three approaches. First, gradual escalation: start with one tablet or capsule daily and adjust every 1 to 2 weeks to response. Second, split dosing. In 20 patients with SjD, switching pilocarpine from 5 mg twice daily to 2.5 mg four times daily (same 10 mg/day) lowered sweating severity at 4 weeks (3.7 to 1.7, p<0.001) and subjective dryness (VAS 61.0 to 43.6, p=0.011). Urinary frequency and oral satisfaction did not change significantly.

Third, he presented a mouth rinse option. One day’s supply (3 cevimeline capsules, or 3 pilocarpine granule sachets, the latter marketed only in Japan) is dissolved in 150 mL of water and used in six or more divided doses: a small amount held in the mouth for 2 minutes, then swallowed. In 12 patients with SjD, cevimeline in juice raised unstimulated salivary flow more than juice alone at 1 and 2 hours.

Taken together, Dr. Moriyama’s message is practical: rule out other contributors, check how much gland function remains, and match therapy to it. For muscarinic agonists, slow titration, divided doses or a mouth rinse may make them easier to stay on long enough to see benefit. The supporting data are limited and dated, though, and the rinse still lacks tolerability data, so larger controlled studies are needed. Because reduced saliva harms oral health beyond the sensation of dryness, dentists and routine oral health checks belong alongside rheumatology care in SjD.